Compare LDI & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LDI | TSHA |
|---|---|---|
| Founded | 2010 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 542.4M | 1.7B |
| IPO Year | 2021 | 2020 |
| Metric | LDI | TSHA |
|---|---|---|
| Price | $0.69 | $4.91 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | $3.00 | ★ $11.63 |
| AVG Volume (30 Days) | ★ 6.3M | 2.2M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 5.56 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $9,773,000.00 |
| Revenue This Year | $17.58 | N/A |
| Revenue Next Year | $13.99 | $1,152.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 17.28 |
| 52 Week Low | $0.68 | $3.04 |
| 52 Week High | $3.80 | $7.30 |
| Indicator | LDI | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 37.84 | 38.74 |
| Support Level | $0.68 | $4.37 |
| Resistance Level | $1.32 | $6.01 |
| Average True Range (ATR) | 0.07 | 0.21 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 17.35 | 31.37 |
loanDepot Inc provides nonbank consumer lending solutions for individuals in the United States. It offers personal, residential home, home refinancing, mortgage and home equity loans. It serves customers through distribution channels, including consumer direct centres, retail branches, wholesale centres, and consumer finance and servicing centres in the United States. It competes with commercial banks and financial institutions.
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.